These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32889347)

  • 1. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia.
    Oliveira ML; Rocha A; Nardotto GHB; Pippa LF; Simões BP; Lanchote VL
    J Pharm Biomed Anal; 2020 Nov; 191():113576. PubMed ID: 32889347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin.
    Bains OS; Szeitz A; Lubieniecka JM; Cragg GE; Grigliatti TA; Riggs KW; Reid RE
    J Pharmacol Exp Ther; 2013 Nov; 347(2):375-87. PubMed ID: 23995598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women.
    Benzi JRL; Rocha A; Colombari JC; Pego AMG; Dos Santos Melli PP; Duarte G; Lanchote VL
    J Pharm Biomed Anal; 2023 Oct; 235():115635. PubMed ID: 37634358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.
    Paul C; Baurain R; Gahrton G; Peterson C
    Cancer Lett; 1980 Jun; 9(4):263-9. PubMed ID: 6930988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
    Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive LC-MS/MS Methods for Amphotericin B Analysis in Cerebrospinal Fluid, Plasma, Plasma Ultrafiltrate, and Urine: Application to Clinical Pharmacokinetics.
    Pippa LF; Marques MP; da Silva ACT; Vilar FC; de Haes TM; da Fonseca BAL; Martinez R; Coelho EB; Wichert-Ana L; Lanchote VL
    Front Chem; 2021; 9():782131. PubMed ID: 34912784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.
    Paul C; Tidefelt U; Liliemark J; Peterson C
    Leuk Res; 1989; 13(2):191-6. PubMed ID: 2927175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
    Robert J; Rigal-Huguet F; Hurteloup P
    Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
    Paul C; Liliemark J; Tidefelt U; Gahrton G; Peterson C
    Ther Drug Monit; 1989; 11(2):140-8. PubMed ID: 2718219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
    Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
    Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis of daunorubicin and its metabolite daunorubicinol interaction with apoptotic and drug resistance proteins using
    Rai AK; Satija NK
    J Biomol Struct Dyn; 2023 Dec; 41(20):10737-10749. PubMed ID: 36907598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.
    Cusack BJ; Young SP; Olson RD
    Cancer Chemother Pharmacol; 1995; 35(3):213-8. PubMed ID: 7805179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.
    Drevin G; Briet M; Bazzoli C; Gyan E; Schmidt A; Dombret H; Orvain C; Giltat A; Recher C; Ifrah N; Guardiola P; Hunault-Berger M; Abbara C
    Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.
    Eksborg S; Ehrsson H; Andersson B; Beran M
    J Chromatogr; 1978 Jun; 153(1):211-8. PubMed ID: 659557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters.
    Sorf A; Novotna E; Hofman J; Morell A; Staud F; Wsol V; Ceckova M
    Biochem Pharmacol; 2019 May; 163():290-298. PubMed ID: 30826329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
    Cusack BJ; Young SP; Vestal RE; Olson RD
    Cancer Chemother Pharmacol; 1997; 39(6):505-12. PubMed ID: 9118462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
    Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
    J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
    Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J
    Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).
    Callies S; de Alwis DP; Mehta A; Burgess M; Aarons L
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):39-48. PubMed ID: 15045528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.